Data on 196 diabetes patients who underwent percutaneous coronary intervention with a bare-metal stent showed those who received colchicine had an in-stent restenosis rate of 16%, compared with 33% in the placebo group. Colchicine-treated patients also had lower rates of late lumen loss than those in the control group, researchers wrote in the Journal of the American College of Cardiology.

Related Summaries